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Abstract
Retroviral insertional mutagenesis (RIM) is a powerful tool for cancer genomics that was combined in this study with deep
sequencing (RIM/DS) to facilitate a comprehensive analysis of lymphoma progression. Transgenic mice expressing two
potent collaborating oncogenes in the germ line (CD2-MYC, -Runx2) develop rapid onset tumours that can be accelerated
and rendered polyclonal by neonatal Moloney murine leukaemia virus (MoMLV) infection. RIM/DS analysis of 28 polyclonal
lymphomas identified 771 common insertion sites (CISs) defining a ‘progression network’ that encompassed a remarkably
large fraction of known MoMLV target genes, with further strong indications of oncogenic selection above the background
of MoMLV integration preference. Progression driven by RIM was characterised as a Darwinian process of clonal competition
engaging proliferation control networks downstream of cytokine and T-cell receptor signalling. Enhancer mode activation
accounted for the most efficiently selected CIS target genes, including Ccr7 as the most prominent of a set of chemokine
receptors driving paracrine growth stimulation and lymphoma dissemination. Another large target gene subset including
candidate tumour suppressors was disrupted by intragenic insertions. A second RIM/DS screen comparing lymphomas of
wild-type and parental transgenics showed that CD2-MYC tumours are virtually dependent on activation of Runx family
genes in strong preference to other potent Myc collaborating genes (Gfi1, Notch1). Ikzf1 was identified as a novel
collaborating gene for Runx2 and illustrated the interface between integration preference and oncogenic selection.
Lymphoma target genes for MoMLV can be classified into (a) a small set of master regulators that confer self-renewal;
overcoming p53 and other failsafe pathways and (b) a large group of progression genes that control autonomous
proliferation in transformed cells. These findings provide insights into retroviral biology, human cancer genetics and the
safety of vector-mediated gene therapy.
Citation: Huser CA, Gilroy KL, de Ridder J, Kilbey A, Borland G, et al. (2014) Insertional Mutagenesis and Deep Profiling Reveals Gene Hierarchies and a Myc/p53-
Dependent Bottleneck in Lymphomagenesis. PLoS Genet 10(2): e1004167. doi:10.1371/journal.pgen.1004167
Editor: H. Leighton Grimes, Cincinnati Children’s Hospital Medical Center, United States of America
Received September 26, 2013; Accepted December 23, 2013; Published February 27, 2014
Copyright:  2014 Huser et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a joint programme grant from Cancer Research UK and Leukaemia & Lymphoma Research (to JCN and EC). JdR is
supported by a VENI grant (639.021.233) from NWO (Netherlands Organisation for Scientific Research). AGR and DJA were supported by Cancer Research UK and
the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ar12@sanger.ac.uk (AGR); James.Neil@glasgow.ac.uk (JCN)
Introduction
The oncogenic potential of murine c-retroviruses (MLVs) stems
from proviral integration into host DNA, a mutagenic process
which can result in activation or disruption of critical host cell
genes [1]. Moreover, by sequential integrations in the nascent
tumour cell, MLVs can drive multiple steps in the oncogenic
process. These features have led to the use of MLVs as screening
tools for genes relevant to cancer, particularly haematopoietic
malignancies. The reach of this approach has grown considerably
with the development of high throughput methods for cloning and
sequencing analysis of host-virus junctions at insertion sites,
facilitating screens of large tumour panels and identifying
hundreds of genes of potential relevance to cancer. Importantly,
genes identified by this method frequently map to orthologous sites
of mutation in human cancer [2,3]. Moreover, retroviral
insertional mutagenesis (RIM) provides a complementary ap-
proach to whole genome sequencing and copy number analysis in
cancer, as RIM has the potential to uncover genes that are rarely
mutated but more commonly subject to indirect processes
including epigenetic modification [4]. Furthermore, large scale
analyses of co-occurrence of target genes can identify patterns
indicating collaborative or redundant relationships between cancer
genes [5,6]. Despite the wealth of information provided by these
studies, it is not yet known whether two events are sufficient for
lymphoid transformation or whether higher order collaborations
between more than two target genes are required. Target gene
interactions can be explored functionally when combined with
manipulation of the mouse genome and mice with an activated
oncogene or mutant tumour suppressor gene in the germ-line
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often show accelerated tumour onset [7,8]. RIM tagging in this
context reveals preferential targeting of specific collaborating
genes, which can be confirmed by analysis of compound
transgenic mice [1].
Moloney murine leukaemia virus (MoMLV) is an oncogenic c-
retrovirus that has been widely used in RIM studies [3,9,10] and
owes its potency to a duplicated enhancer element in the proviral
long terminal repeats (LTRs) [11]. Notably, the LTRs and
backbone of this virus formed the basis of retroviral vector systems
used in early trials of human gene therapy, where leukaemia
resulting from insertional activation of host genes has been a
significant adverse outcome [12]. In mice, the target genes for
MoMLV that have been identified to date show a predominance
of oncogene activation events over tumour suppressor disruption,
consistent with the observed low rate of loss of heterozygosity in
MoMLV lymphomas [13]. However, these findings presented a
long-standing puzzle in light of the effect of germ-line inactivation
of the major tumour suppressor p53, which confers rapid onset T-
cell lymphomas with a similar broad phenotypic spectrum to
MoMLV but shows relatively weak cooperation with MoMLV
[14]. We hypothesised previously that the MoMLV oncogenic
programme must neutralise the tumour suppressor activity of p53,
circumventing the need for direct mutations in the pathway
[14,15]. In support of this proposal we showed that the potent
combination of two MoMLV target genes, Myc and Runx2, could
overcome the need for genetic inactivation of the p53 pathway,
despite the fact that both oncogenes evoke p53 growth suppression
and collaborate strongly with p53 deficiency [16]. Nevertheless,
this combination still appears to be insufficient for full transfor-
mation, as double transgenic tumours emerge as clonal outgrowths
from a polyclonal premalignant phase [17]. We showed previously
that tumour onset could be accelerated by retroviral infection and
a RIM screen identified a number of candidate third hit genes,
including Pim1, a gene that accelerates tumour onset when
combined with MYC/Runx2 in the germ-line [9,18].
In this study we have conducted a further screen on the same
progressing lymphomas, using a deep sequencing method
(splinkerette/454) which is orders of magnitude more sensitive
than previous shotgun cloning methods. Sequencing at this depth
raises another potential concern, as c-retroviruses including
MoMLV display preferential integration at transcriptional start
sites and other chromatin feature that may also entail a bias
towards proto-oncogenes [19–21]. However, we present multiple
lines of evidence for post-integration selection as the dominant
force shaping the progression ‘integrome’. Moreover, we find that
a surprisingly large fraction of the known MoMLV target gene
spectrum is detectable in the integrome, indicating that any one
among hundreds of genes can contribute to driving clonal
outgrowth. However, there is a clear hierarchy of target genes
that are selected from a large gene pool generated by the intrinsic
preferences of c-retrovirus integration. Another striking finding is
the genetic bottleneck to transformation imposed by transgenic
CD2-MYC, which is highly dependent on Runx gene activation.
Comparison with other transgenic models of Myc over-expression
shows that these each display potent selection from a small pool of
master collaborating genes. These genes share the capacity to
suppress the p53 pathway but are differentially recruited according
to lymphoid lineage and developmental stage. The identification
of a small gene set that confers the lymphoma initiating cell
phenotype and is conserved in human disease has significant
implications for targeted interventions.
Results
Deep sequencing of progressing lymphomas reveals a
Darwinian clonal selection process involving many target
genes
Relevant features of the CD2-MYC and CD2-Runx2 transgenic
mice are displayed in Figures 1 and S1. The disease-free survival
of most parental transgenic mice has been attributed to
variegated expression under CD2 locus control region (LCR)
control [22] along with counter-selection by failsafe processes
[22,23]. As previously described [9,17,23], co-expression of both
transgenes results in rapid onset lymphomas in 100% of mice,
but the tumours typically display a single predominant clone as
illustrated by T-cell receptor gene rearrangement (Figure S1).
Neonatal infection with MoMLV leads to accelerated lymphoma
onset, increased clonal complexity and lymphoid dissemination,
although the tumours retain the characteristic bimodal pheno-
type seen in the absence of infection (CD8+,CD4+/2,TCRhi)
[16].
Here, a panel of 28 lymphomas was analysed by RIM/DS
(splinkerette/454). Processing of reads as described in Methods
yielded 12,485 unique retroviral insertion sites (RISs), compared
to 272 by previous manual cloning and sequencing methods [9].
Common insertion sites (CISs) were identified using a multi-scale
Gaussian Kernel Convolution approach [24] yielding 771
significant CISs compared to 0–3 expected from simulations of
random integration (Table S1). A list of all RIS is provided as a
.bed file for visualisation in genome browsers, version mm9
(Table S2). Notably, analysis of CIS accrual by number of
tumours indicated that this system is approaching saturation and
that virtually all the retrievable CISs have been detected
(Figure 1D). Target genes affected by integration at CISs were
identified by computational methods [25] followed by manual
curation.
All 14 target genes identified by shotgun cloning methods [26]
featured prominently (Figure 1E; Table S3). There was a positive
correlation between the number of clones previously detected by
shot-gun cloning and the number of 454 reads (linear regression
analysis; R=0.56) showing that earlier lower powered methods
Author Summary
Cancers are known to arise by a series of mutational and
non-mutational (epigenetic) events but the advent of
cancer genome sequencing highlights the growing chal-
lenge of separating important (driver) from irrelevant
(passenger) mutations. Retroviruses that induce cancer by
inserting into host DNA and thereby altering key genes are
valuable tools because they act as ‘tags’ to identify the
critical targets. In this study we combined retroviral
tagging with next generation sequencing to achieve a
comprehensive description of lymphoma development
and progression in transgenic mouse model systems. Our
study suggests that three events may be sufficient for
lymphoma development and identifies a genetic bottle-
neck at a small gene set that regulates tumour cell self-
renewal, including the Myc oncogene and the p53 tumour
suppressor. In contrast, many genes can provide the final
step where the lymphoma cell acquires the ability to
divide independently of external stimuli. As many of the
target genes are conserved and play roles in cancers of
non-viral origin, this study may provide a paradigm for the
gene interactions that underlie cancer biology. It also
elucidates the risks entailed in the recent use of retrovirus-
based vectors for human gene therapy.
Bottlenecks to Oncogenesis
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detect only the ‘‘tip of the iceberg’’ of clonal expansion. While
splinkerette/454 analysis is only semi-quantitative due to restric-
tion enzyme site distribution and primary sequence constraints on
PCR efficiency, we noted that the most abundant RIS corre-
sponding to Pim-1 insertions were also detectable as rearrange-
ments by Southern blot analysis (Figure S2). Moreover, the top 40
RISs (by number of reads) show few apparent passenger insertions,
defined as isolated RIS far from any known target gene (5/40),
although these predominate (85%) in the total population of
12,485 RISs. The possibility that most of these clones have
acquired two separate driver insertions without any passenger
insertions appears unlikely, suggesting that most highly prolifer-
ative clones contained only a single provirus.
Comparison with CISs from end-stage MoMLV
lymphomas reveals major overlap
If the progression network consists of target genes that can com-
plete the oncogenic transformation process, they would be expected
to feature strongly in the dominant clones found in end-stage
MoMLV-induced lymphomas. To test this assumption, we exam-
ined the overlap between the 771 progression CISs in this study with
a meta-analysis by Kool and co-workers involving CISs identified by
shotgun cloning of 19,923 unique RIS from 977 MoMLV-induced
lymphomas of wild-type or tumour suppressor deficient mice [3].
Due to the lower sensitivity of the approach, these CISs should be
enriched for major expanded tumour clones. A remarkable 346
CISs (45%) were found in common between the Kool CISs and the
progression CISs, indicating that a significant proportion of the
target genes involved have been implicated previously as drivers of
lymphoma development (Figure 2A, Table S4).
Further evidence of oncogenic selection: orientation bias
and network analysis
Preferential integration of c-retroviruses around transcriptional
initiation sites is an established phenomenon [19] and on the basis
of this and further evidence of non-random behaviour it has been
Figure 1. (A) Features of the system and experimental design of the RIM/DS progression screen (see also Figure S1). Mice carrying
CD2-MYC or CD2-Runx2 transgenes each develop a low incidence of lymphoma, while double transgenics develop lymphomas early with 100%
penetrance. (B) Infection of double transgenic mice with MoMLV increases the rate of lymphoma development and the clonal complexity of the
resulting tumours. (C) Flowchart of sequencing analysis: Splinkerette clones from 28 double transgenic tumours were sequenced by Roche 454 to
identify 12,485 unique retroviral insertion sites (RISs). Gaussian kernel convolution statistical analysis identified 771 common insertion sites (CISs). (D)
Saturation analysis of common insertion sites from the 28 MoMLV-accelerated thymic lymphomas. The number of genomic bases covered by
predicted CISs increases as the number of samples used increases. The increase is linear if RIS are randomly distributed (upper) but approaches
saturation in our real dataset (lower), indicating that 28 samples is sufficient to identify almost all positively selected CISs in this experimental system.
(E) The 25 most frequently targeted CISs ranked by number of individual RISs. The right-hand panel shows the average number of reads for RIS. Red
bars denote those detected in a previous shotgun cloning screen, with numbers denoting the number of clones detected [9]. A positive correlation
(R = 0.56) was noted between with the number of reads/RIS and likelihood of detection by the lower-powered shotgun cloning methodology.
doi:10.1371/journal.pgen.1004167.g001
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argued that the observation of a CIS is insufficient evidence that
post-integration selection for growth has occurred, particularly in
large scale analyses [27]. While the ideal comparison with the
progression CISs identified here would be normal thymocytes
immediately after infection, there are significant technical
challenges in obtaining a reliable in vivo baseline measurement
due to the kinetics of infection and ongoing replication. We
therefore chose to compare some aspects of our data to a published
large-scale study of human CD34+ cells obtained after in vitro
infection with a non-replicating MLV vector. This study by
Cattoglio et al. is described as ‘near-baseline’, as analysis was not
carried out until 10 days post-transduction [21].
Notably, preference for transcriptional start sites was relaxed in
the CISs observed in our study and this trend was more evident
still in CISs with an orientation bias, consistent with the increasing
importance of post-integration oncogenic selection in this subset
(Figure 2B). Moreover, we noted that most of the highly targeted
CISs displayed the pronounced orientation bias that is classically
Figure 2. (A) Comparison between CISs detected in 19,900 MoMLV insertions derived from 937 lymphomas by shotgun cloning [25]
and the progression CISs defined in this study. There is substantial overlap in the CISs detected. (B) Peak distance of RISs from the nearest
transcription start site (TSS). RISs that fall outside CISs (bottom panel) display a distribution similar to that reported for unselected MoMLV insertions
[19,21], and strongly cluster around the TSS. RISs that comprise the ‘biased CIS’ set (top panel) display a relaxed clustering at TSS, while ‘non-biased
CIS’ set present an intermediate picture. (C) Orientation bias analysis of 771 progression CISs. Bias is plotted against the number of RISs in each CIS
(after Benjamini-Hochberg correction for multiple testing). Those with a p-value ,0.05 define the ‘biased CIS’ set, and the others the ‘non-biased CIS’
set. (D) Examples of orientation bias of RISs targeting Ccr7, Ccnd1 and Ahi1/Myb. Each vertical bar represents an individual RIS, coloured to depict
orientation (green forward, red reverse) relative to the DNA+strand. Positions of exons and introns are abstracted from the UCSC genome browser
(NCBI37/mm9). Percentages refer to predominant orientation at each CIS. Notably, this analysis implicates Myb as the target of long-range insertions
from both 59 and 39 ends.
doi:10.1371/journal.pgen.1004167.g002
Bottlenecks to Oncogenesis
PLOS Genetics | www.plosgenetics.org 4 February 2014 | Volume 10 | Issue 2 | e1004167
associated with enhancer-mode gene activation [1]. As orientation
bias does not arise at the level of integration [28], this feature
provides direct evidence of post-integration clonal selection.
Stringent filtering of CISs for orientation bias yielded 17 examples
which we will refer to as biased CISs (Figure 2C; Table S5). We
applied the same approach to the Cattoglio ‘near-baseline’ dataset
[21] and found no clusters with significant orientation bias after
correction for multiple testing. CIS target genes displaying strong
orientation bias were also the most frequently targeted and often
displayed the greatest levels of clonal expansion, suggesting that
enhancer mode activation is the most efficient process by which
MoMLV drives lymphoma progression.
An interesting outcome of this analysis shown in Figure 2D is
that it provides strong support for the Myb gene as the target of
long-range activation by insertions both 59 and 39, including the
CIS annotated as Ahi1, in accord with hypotheses based on gene
expression studies in lymphoma cell lines [29,30]. Further
examples of genes subject to enhancer mode insertions are shown
in Figures 2D and S3.
Evidence that the biased CIS targets form part of a larger
progression network under selection was provided by KEGG
pathway analysis which showed that some of the most frequent CIS
targets (e.g. Ccnd3, Ccr7, Pik3cd, Pik3r5, Rasgrp1) map to metanodes
that include many of the less frequent targets (Figure S4).
Furthermore, KEGG pathway enrichment analysis showed that
statistically significant over-representation of specific signalling
pathways (T-cell receptor, chemokine, JAK-STAT) was evident
even when the top 50–100 target genes were excluded from the
analysis (P=,1610E-5), arguing that oncogenic selection may also
be occurring at sites that harbour only a few insertions (Figure S5).
While orientation bias is useful to identify oncogenic selection
on a background of preferential integration, we noted that there
was a second frequent CIS group defined by intragenic insertions
that displayed no statistical bias in orientation. Evidence that these
are also under oncogenic selection is provided by the fact that 17
of the 20 most frequent targets have been observed in end-stage
lymphomas (Table S6) and by the fact that a significant subset
have annotation suggestive of tumour suppressor or oncogene
function (Ikzf3, Mad1l1, Als2, Ppp1r16b, Prex1, Ttc28 and Ptprc). The
typical pattern of insertions distributed across the target genes is
suggestive of a tumour suppressor role, although a role for
oncogenic truncated isoforms is also plausible [1,9,31]
The progression network provides strong evidence of
complementation
Although the majority of top ranking MLV target genes were
shared between our progression dataset and the Kool meta-
analysis of end-stage lymphomas, there were also notable
differences. This was evident from comparison of CIS peak
heights and relative rank order of CISs between the datasets where
the most discordant examples are listed (Table S7). Oncogenic
complementation was evident, with greatly reduced targeting of
Myc/Pvt1, Mycn and Runx family genes in the progression set.
However, there was also a marked loss of selection for some major
targets recorded by Kool et al. including Gfi1 and Notch1. It appears
that the combination of MYC and Runx2 in this context also
renders these insertions redundant, which is intriguing as
insertions at Gfi1 have been shown to be positively selected in
some CD2-Runx2 lymphomas [18].
Also of interest was the large number of novel CISs in the
progression set (Table S8, examples shown in Figure S3). The most
frequently targeted CIS targets displaying strong evidence
of enhancer mode activation included Otx2, a homeobox
transcription factor which plays a major oncogenic role in
medulloblastoma [32] but has not previously been observed in
haematopoietic cancers and Myo16, an atypical nuclear myosin
with links to survival, cell cycle progression and PI3K signalling
[33]. Moreover, a number of prominent targets for potentially
disruptive intragenic insertions were unique to the progression set.
These included Endou (Pp11), a placental poly-U endonuclease
over-expressed in ovarian adenocarcinomas [34], Xrra1, which has
been shown to modulate the response to X-ray irradiation [35],
and Ttc28 (Tprbk), encoding a large tetratricopeptide domain
protein that is regulated by p53, complexes with BRCA1 and
suppresses the growth of Ras-transformed cells [36].
The transcriptome of prelymphoma MYC/Runx2 thymus
provides insights into progression gene selection and
chemokine-receptor interplay in lymphoma
dissemination
A previously published analysis of preferential integration
targets in early passage CD34+ cells showed a good correlation
between basal transcriptional levels and integration frequency
[21]. To test whether progression RIS targets were also selected by
their high transcription rates in premalignant cells, we compared
the transcriptomes of Runx2/MYC and control thymus at 10 days
of age, several weeks before clonal tumours emerge. Figure 3
shows expression scatter plots for all gene probes. Basal expression
of the most prominent progression targets was widely variable, and
only Ccnd1 showed significant up-regulation compared to control
thymus. Moreover, the frequent MoMLV targets that were not
enriched in the progression network showed a similarly wide
distribution with regard to expression levels. The exquisite selection
by RIM of specific members of multigene families (e.g. Jdp2,
D cyclins) also appeared to be poorly correlated with expression
level, strengthening evidence for post-integration selection as the
predominant force shaping the progression network.
Frequent targeting of Ccr7, and to a lesser extent Ccr9, is
interesting in view of their central roles in mediating T-cell
progenitor homing to thymus [37,38]. Moreover, Ccr7 has been
reported as a mediator of progression and homing to lymph nodes
in multiple tumour types, and to stimulate survival pathways by
autocrine or paracrine mechanisms [39]. The cognate ligands for
Ccr7 and Ccr9 (Ccl21a, Ccl19, Ccl25), are highly expressed in
normal thymus, but intriguingly were significantly down-regulated
genes in premalignant organs (validation shown in Figure S6). The
respective chemokine genes are normally expressed only in non-
lymphoid elements of the thymus including epithelial cells [40]. The
possibility that these genes were aberrantly activated to drive
autocrine growth in the lymphoma cells was tested by direct analysis
of isolated lymphoma cells (Figure S7). However, expression of the
ligand genes was below detectable levels in Runx2/MYC or CD2-
MYC/p53 null lymphoma cells suggesting that activation of Ccr7/9
provides a growth advantage by a paracrine mechanism that is
dependent on thymic stroma. Falling expression of ligand genes in
10-day Runx2/MYC thymus may be due to down-regulation or
simple occlusion of non-lymphoid cells by nascent lymphoma cells,
which is virtually complete at later stages (Figure S1).
Analysis of single transgenic tumours reveals a Myc-
directed bottleneck and collaboration between Runx2
and Ikzf1
To compare the progression network with genes selected during
earlier events in tumorigenesis, a second RIM/DS barcode screen
was conducted, including MoMLV-infected end-stage lymphomas
from parental CD2-MYC, -Runx2 and wild-type mice with a subset
of Runx2/MYC progressing tumours (Figure 4, Table S9). All
Bottlenecks to Oncogenesis
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insertions, sorted by genotype are provided as a .bed file for
visualisation in genome browsers, version mm9 (Table S10). MYC
and Runx2 transgenes each cooperate with MoMLV to accelerate
lymphoma onset to around 60 days post-infection [8,17,18].
Compared to MYC/Runx2, the other three tumour sets yielded
many more reads, but from a much smaller number of unique
RISs, reflecting the presence of highly expanded tumour clones
(Figure 4A, B). The massive number of RISs per tumour (221–276)
shows that in MoMLV lymphomas the predominant end-stage
clones co-exist with a polyclonal background of minor populations.
Application of an abundance threshold of 100 copies (Figure 4B)
yielded a RIS number close to that expected from Southern blot
analyses of end-stage MoMLV tumours that estimated 4–6 RISs in
each dominant clone [41]. In most cases this cut-off correlated well
with previous direct analyses for gene rearrangement [18,42],
although rearrangements of Myc detected by Southern blot in two
of the CD2-Runx2 tumours analysed here failed to register in the
splinkerette/454 analysis. Occasionally ‘missing’ clones might be
explained by technical limitation e.g. due to sequence drift in
primer sequences. In this regard, it is noted that the bias towards
Myc family insertions was less marked here than in a Southern
blot-based analysis of a larger CD2-Runx2 tumour cohort [18].
Nevertheless, there were clear and profound differences between
cohorts, as MYC transgenic tumours resolved into fewer clones
with substantially greater clonal enrichment compared to other
genotypes while the double transgenics showed greater complexity
as expected (Fig. 4B, C). This apparent difference in the mode of
tumour acceleration is interesting as CD2-Runx2 mice harbour an
expanded population of transformation-prone thymocytes, which
has no parallel in CD2-MYC mice, most of which remain healthy
with no obvious abnormality [8,16,43].
The most striking features of the single transgenic tumours were
evident when the most abundant RISs were sorted according to
gene family (Figure 4C, D). High copy RIS mapping to Runx2 or
Runx3 were almost ubiquitous in, but exclusive to, CD2-MYC
tumours (P = 0.0001, Fisher’s Exact Test). A number of high
abundance RIS mapped far upstream of Runx2, adding this gene
to the list of those subject to long-range activation. Only two
tumours displayed no detectable Runx insertion.
Another salient observation from analysis of the end-stage
lymphomas was that the low abundance RIS left after subtraction
of the major clones frequently correspond to progression network
genes (Tables S11, S12). It is conceivable that these represent
tumour subclones that have acquired a further hit of proviral
insertion, although the alternative possibility that these represent
insertions in prelymphoma cells cannot be excluded. The possibility
that this background reflects preferential integration in untrans-
formed cells appears unlikely, as such cells form only a tiny fraction
of the thymic mass and the hallmark orientation bias at major
targets (Figure 1C) is also evident in these minor populations.
Moreover, expanded RIS indicative of third hit genes in CD2-MYC,
CD2-Runx2 and wild-type mice appeared to be selected from a
broad cross-section of the progression network, with the ‘winners’ of
the progression race largely recapitulating the expansion rate
measured by earlier analysis of the progression network (Figure 1D).
Second hit genes represent a narrow genetic bottleneck
to transformation
We reasoned that specific ‘second hit’ collaborating genes would
be distinguishable from progression genes on the basis of (a) positive
selection in lymphomas of single transgenic mice compared to wild-
type and (b) loss of selection or reduction to background levels in
double transgenics. As expected, the Runx genes (Runx2 and Runx3)
andMyc family targets (Myc, Mycn) conformed to this pattern, being
selected in CD2-MYC and CD2-Runx2 respectively and effectively
disappearing from the double transgenic tumours (Figure 4C).
Figure 3. Global gene expression analysis in 10 day old (prelymphoma) MYC/Runx2 thymus compared to wild type controls as
determined by Affymetrix microarray. Scatter plots showing relative expression of genes in transgenic vs control mouse thymus with particular
gene sets highlighted as indicated. Target genes positively selected in the progression network are denoted by red dots, others by blue dots (A)
Biased CIS gene set, with annotation of novel targets (B) Common MoMLV target genes absent from, or under-represented in, progression CISs. (C)
Jun family, noting the prominent target Jdp2. (D) Cyclin genes, noting prominent D-cyclin targets (E), CC chemokine receptors, noting prominent
targets Ccr7 and Ccr9, and (F) CC chemokine ligands showing significantly down-regulated Ccl19,21,25.
doi:10.1371/journal.pgen.1004167.g003
Bottlenecks to Oncogenesis
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Surprisingly, inspection of the entire CIS list revealed only one other
target gene with statistically significant correspondence to this
pattern: intragenic insertions in Ikzf1 were significantly more
abundant in CD2-Runx2 transgenic tumours than in the other
three genotypes and showed more frequent representation in
dominant clones (Figure 5). Intriguingly, analysis of the CD34+
‘random integration’ vector dataset [21] shows two hotspots for
integration in the human IKZF1 gene that correspond to active
chromatin marks. The murine Ikzf1 gene showed a similar
background pattern, although 3–4 clusters of insertions could be
discerned in the murine gene. These observations suggest a two-step
model for targeting of Ikzf1 by MoMLV, with preferential
integration at sensitive sites within the gene leading to sustained
clonal expansion only in the presence of a collaborating lesion such
as deregulated Runx expression (Figure 5B).
Table S13 summarises the genes showing strongest evidence
of complementation in parental transgenic mice. In addition,
there is evidence of reduced selection for Gfi1 and Notch1
insertions on the CD2-MYC background which directly mirrors
findings on the progression set compared to common MoMLV
targets (Table S7) suggesting that this bias is conferred by the
CD2-MYC transgene. Targeting of both genes in wild-type
controls and CD2-Runx2 in this study rules out mouse strain
differences as the basis of this phenomenon. Notably, Notch1
has been shown to block p53-dependent apoptosis due to Myc
over-expression [44], while Gfi1 has recently been shown to
modulate p53 responses indirectly by altering protein methyl-
ation [45]. The latter finding illuminates early RIM screens of
Em-Myc mice which suggested that Gfi1 and Bmi1 belong to the
same complementation group [7], and Bmi1 is known to control
Figure 4. (A) Features and design of the RIM/DS complementation screen. Average lifespan (days) of wildtype (WT), CD2-MYC, CD2-
Runx2 and CD2-MYC/Runx2 double transgenic mice, without and with MoMLV infection. Percentage value indicates lifetime lymphoma
incidence. 12 lymphomas from each genotype were analysed by RIM/DS, identifying the indicated number of RISs (total reads in parentheses). (B)
Individual RIS in log rank order according to number of reads. Horizontal dotted line represents 100 reads per RIS and was used as a threshold for
expanded CISs shown in (d). (C) Total reads in each genotype cohort comprising the CISs around Myc/Mycn/Pvt1 (yellow), Ikzf1 (red), Runx2/Runx3
(purple), around other CISs from the biased CIS set (green) or other RISs (grey). The total numbers of RISs that contribute to the overall read count are
indicated outside the pie charts (D) Schematic representation of all RISs with at least 100 reads detected by DS. Each square represents a single RIS,
with colour coding as in (c). Expanded RISs not falling within a CIS (presumptive passenger RIS) are not depicted. These analyses illustrate the reduced
complexity and greater clonal expansion in MoMLV accelerated CD2-MYC tumours.
doi:10.1371/journal.pgen.1004167.g004
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p53 responses by transcriptional suppression of Arf [46]. As we
have shown that Runx2 also inhibits Myc-induced apoptosis in
vivo and that the Runx2/MYC combination neutralises selection
for loss of p53 [16], we propose the model in Figure 6 to account
for the respective gene interactions in different transgenic
backgrounds in a three-hit model of MoMLV lymphomagenesis.
Comparison with murine and human T-cell lymphomas
reveals extensive overlap in common insertion sites and
domains of copy number alteration
The extent to which the pathways targeted in retrovirus-
induced lymphomas overlap with similar tumours of non-viral
origin, including human cancers, is also of considerable
interest. We compared the comprehensive CIS database with
regions of chromosomal gain and loss described in a previous
study of T-cell lymphomas arising in mice defective in
telomerase, p53 and ATM (‘TKO’) mice [47], where a strong
overlap was noted with human T-ALL. Remarkably, 16/18
regions of syntenic deletion or amplification contained CISs,
corresponding to 43/771 CISs (for this overlap P =,0.0001;
Table S14). Notably, no known cancer genes could be found at
the majority of these domains [47], suggesting that the genes
targeted at these CISs represent candidates for gain or loss of
function that is conserved between human and mouse cancers.
Significantly, many of the target genes display intragenic
insertions, particularly for the deleted regions (13/22). An
interesting example is Gpr132, located on chromosome 12,
which encodes a G-protein coupled receptor with apparent
tumour suppressor activity [48].
Figure 5. Insertions at Ikzf1 display dual features of preferential integration and oncogenic selection. A) Upper panel : Inspection of .
32,000 MLV vector integrations in early passage human CD34+ cells (Cattoglio set [21]) shows two clusters of integration in the IKZF1 gene which
map to sites of active chromatin marks (H3K27 acetylation, ENCODE data for 7 cell lines). Lower panel: A pattern of low abundance integrations within
Ikzf1 is present in all 4 genotypes in our study, suggesting a conserved process of preferential integration at the murine gene corresponding again to
chromatin features (H3K27 acetylation in C57/BL thymus). However, many more insertions are evident in the CD2-Runx2 background, and substantial
expansions (.100 reads) in end-stage lymphomas show a similar genotype bias. (B) Diagrammatic model of a two-stage process of oncogenic
selection on a background of MoMLV preferential integration.
doi:10.1371/journal.pgen.1004167.g005
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Discussion
In this study we examined an established system of oncogene
cooperation and retroviral acceleration using a deep sequencing
(DS) platform. RIM/DS increases sensitivity of RIS detection by
almost two orders of magnitude over earlier methodologies [9] and
when applied to a lymphoma progression model shows evidence of
saturation, indicating that all relevant major CISs have been
obtained. The remarkable observation that much of the large
repertoire of MoMLV target genes from almost one thousand end-
stage T-cell lymphomas can be found in the progression network
from only 28 lymphomas shows the enormous potential of RIM/
DS when applied to polyclonal populations under strong selection.
While statistical and pathway analyses provide useful tools to
discriminate genes under oncogenic selection from preferential
integration, our findings suggest that the phenomena may not be
completely separable. The example of Ikzf1 illustrates the principle
whereby a gene may be selectively targeted by c-retroviral
integration but leads to clonal expansion in the presence of a
complementary oncogenic programme provided in this case by
Runx gene activation. It has been demonstrated recently that c-
retroviral integration at transcriptional start sites is a consequence
of interaction with BET chromatin regulators that direct the
process towards genomic regions rich in acetylated histones
[49,50]. The integration specificity of c-retroviruses is clearly
fundamental to their efficient replication and transmission in
nature. In wild-type mice, the rate of oncogenic transformation
due to successive integration events is reduced by retroviral
interference, but the process is accelerated in oncogene transgenic
mice where fewer hits are required.
The implications of our analyses are also interesting for
retroviral vector-based gene therapy. As the most potently selected
insertions mediate enhancer-mode gene activation, the removal of
enhancer elements in self-inactivating vectors [51] is likely to
improve safety margins. However, failure to deal with the
targeting apparatus will leave a residual risk, particularly for gene
disruption events which, from their lack of obvious orientation
bias, may not require strong enhancer function (e.g. at Ikzf1).
While intrinsic preference for integration at transcriptional start
sites and other chromatin features [19–21] creates the platform on
which oncogenic selection operates, it is clear that post-integration
selection events play a decisive role in shaping the genetic profile of
end-stage tumours. The progression network is highly adapted to
the T-cell environment but is not simply a cross-section of highly
expressed and therefore available target genes. This principle is
illustrated by the strong selection for specific members of
multigene families (e.g. Jdp2, D cyclins) that show no correlation
with basal transcription levels. Similarly the targeting of novel
genes that were not seen in previous large-scale screens of
MoMLV-induced T-cell lymphomas (e.g. Otx2, Myo16) is not
merely due to their up-regulation in the background of the Runx2/
MYC model. These findings suggest that it will be of value to
employ RIM/DS to probe the growth checkpoint networks in
tissues and cell lineages that have been less well explored to date.
While most of the functionally annotated progression network
genes are predicted to confer autonomous proliferation, an
exception to this rule was provided by the frequent activation of
Ccr7 and Ccr9, which in their normal developmental roles promote
T-cell homing to thymus and ligand-dependent survival and
proliferation [37]. Moreover, Ccr7 is stimulated by Notch
signalling [52], and we would predict that retroviral activation
bypasses this requirement. It appears that the result of Ccr7/9
activation in Runx2/MYC lymphomas is likely to be paracrine
growth stimulation, as expression of the cognate ligands (Ccl19,
21, 25) is restricted to thymic stromal cells. Moreover, declining
levels of ligand transcripts in Runx2/MYC thymus offers a
rationale for the accelerated dissemination of lymphoma cells
towards highly expressing peripheral lymphoid tissues [9]. Export
Figure 6. Hierarchical model of MoMLV-induced T-cell lymphomagenesis and preferred target genes in Myc transgenic systems. In
this model, critical genes in lymphoma initiation and establishment converge on Myc and p53, while Ikzf1 insertions are postulated to de-repress c-
myc [31,67]. Lymphoma phenotype and preferred target genes vary according to expression control element and lineage [7,53,56]. A much larger set
of target genes and downstream pathways is capable of driving clonal expansion at the tumour progression stage.
doi:10.1371/journal.pgen.1004167.g006
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of lymphoma cells with Ccr7 insertions is also in accord with the
relatively low read/RIS ratio in primary thymic lymphomas.
Identification of Ccr7 as a major target highlights the complemen-
tary value of RIM screening, as this gene does not appear to be
subject to mutation or amplification in human cancer, yet is
required for CNS metastasis of human leukaemia cells [52].
Comparison of the progression network with a large scale meta-
analysis of MoMLV targets in T-cell lymphomas from various
genetic backgrounds [3] showed that the principles of comple-
mentation apply where the two germ-line oncogenes are present,
as insertions at Myc and Runx family members were massively
under-represented in the progression set. Moreover, while most
major targets overlapped strongly, a few prominent targets
including Gfi1 and Notch1 were also greatly diminished in the
progression network. Our second RIM/DS of parental transgenic
mice shed further light on this observation, as the CD2-MYC
parental transgenic system in particular did not select for these
targets but instead showed virtual dependence on activation of a
Runx family gene with the order Runx2.Runx3.Runx1 in targeting
frequency in accord with previous observations [53–55]. Com-
parison of several Myc transgenic model systems (CD2-MYC, Em-
Myc, Mmtv(d)-Myc) shows that these have massively divergent
preferences for collaborating genes detected by RIM, presumably
reflecting the lineage and stage-specificity of Myc expression
control [7,42,56]. However, it is notable that all of these potently
selected collaborating genes share the ability to suppress the p53
response in the context of activated Myc [16,44,46,57]. There is
an obvious parallel with the observation that the combination of
CD2-Runx2/MYC overcomes the requirement for genetic
inactivation of the p53 pathway [16], providing a rationale for
the reduced selection for Notch and Gfi1 on this background.
The foregoing observations invite themodel presented in Figure 6,
where the interaction of this small gene set is presented as a
bottleneck to transformation in contrast to the broad range of pro-
gression genes that can be recruited at later stages. In addition to the
simple outline shown here, it appears that the MoMLV ‘core’ gene
programme can also neutralise p53-independent failsafe pathways,
as p53 deficiency has relatively modest effects on MoMLV-induced
tumour onset and target gene spectrum [5,14,15]. It should also be
noted that at least some of the genes in the progression network can
also serve as initiators when expressed as transgenes, showing that
the mutational order may not be fixed [58–60].
Why do the major collaborating gene targets vary so markedly
between Myc transgenic models? The most obvious rationale is
presented by the lineage and stage-specificity of Myc expression.
RIM targeting of Bmi1 is largely a feature of B-cell lymphomas in
the mouse [7], while Notch targeting predominates in the CD4+
CD8+ lymphomas of Mmtv(d)-Myc mice [56]. The CD2 LCR
confers strong T-cell specificity but is also active in B-cells [61],
implying that its developmental activation may occur at the level
of committed lymphoid progenitors. High level Myc expression in
this niche appears to lead to cell death, unless combined with loss
of p53 or an activated Runx allele [17,62,63]. We hypothesise that
Notch1 or Gfi1 pathways are not available for RIM targeting at this
stage and that Runx2, the ‘bone-specific’ family member, which is
also transcriptionally active in early haematopoietic development
[64], becomes the primary target for activation in this niche. As
mounting evidence indicates that Runx family members are
downstream of Notch signalling in expression control and effector
functions [65], it is tempting to suggest that dual activation of Runx
and Myc supplants the need for activation of Notch. The model we
propose has implications for therapeutic targeting of Notch
signalling with c-secretase inhibitors [66], as up-regulation of
Runx and Myc may represent another pathway to resistance.
Although CD2-Runx2 selects strongly for activation of Myc
family genes by RIM [18] it appears less critically dependent,
possibly due to the survival of Runx2 expressing thymocytes as a
premalignant, slowly proliferating population blocked at the DN/
CD8ISP stage [43]. This study shows that Ikzf1 is also favoured as
a collaborating target on this background. Notably, Ikzf1 is a
haplo-insufficient tumour suppressor that has been reported to act
as a transcriptional suppressor of Myc [67], while intragenic
retroviral insertions lead to expression of truncated isoforms with
dominant negative potential [31]. We therefore suggest that de-
repression of Myc may be one of the consequences of Ikzf1
targeting that leads to its co-selection with Runx2. It would
interesting in this regard to test whether lymphomas of Runx2
transgenic mice with reduced Ikzf1 function [68] would show
reduced RIM targeting of both Myc family genes and Ikzf1.
This analysis has wider implications for the genetics of human
lymphomas and other cancers. It appears that the final step in
lymphoid transformation by MLV can be accomplished by a wide
range of genes with the common functional end-point of growth
factor-independent proliferation. As the progression network also
includes numerous genes that are mutated, amplified or deleted in
human cancer (Table S14), it is tempting to suggest that many of
the acquired mutations in human cancer are also late embellish-
ments. Another important insight is provided by the evidence of a
small network of genes (Myc, Runx, Ikzf1, Gfi1, Notch1, and Bmi1)
that act in pairwise combinations to confer lymphoma self-renewal
and overcome failsafe responses via the p53 pathway. It seems
likely that this network operates under normal physiological
conditions to licence cell growth and is co-ordinately subverted in
cells carrying mutations in the pathways. The recent description of
Gfi1 as an ‘oncorequisite’ factor that is rarely directly mutated but
nevertheless required for growth of ALL cells [45] highlights the
potential for targeting this network. The Runx genes are heavily
implicated in human leukaemia but show paradoxical features of
either gain or loss of function in disease subsets [69]. The
demonstration here that Runx activation is virtually essential for
MYC transformation of early murine T-cell lymphoma suggests
that it may be fruitful to examine the requirement for RUNX
function in human leukaemia/lymphomas driven by amplified
MYC or NOTCH/IKZF1 mutations.
Methods
Ethics statement
Animals were routinely monitored and sacrificed when showing
signs of ill health in line with the UK Animals (Scientific
Procedures) Act, 1986.
Animals
CD2-MYC, CD2-Runx2, and CD2-MYC/CD2-Runx2 transgenic
animals and maintenance were described previously [9]. Neonates
were infected within 24 hours of birth with ,105 infectious units
of MoMLV as previously described [42]. Littermate-matched
genotype controls were used to control for mouse strain.
DNA extraction
DNA was extracted from approximately 20 mg of frozen
enlarged lymphoid/tumour tissue using Gentra Puregene Geno-
mic DNA Purification Kit (Qiagen, UK) according to the
manufacturer’s instructions.
Isolation of retroviral insertion sites
Isolation of the retroviral insertion sites from the tissues was
performed using splinkerette PCR to produce barcoded PCR
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products that were pooled and sequenced on 454 GS-FLX
sequencers (Roche Diagnostics platform) as described previously
[70,71]. The restriction enzymes used to digest the genomic DNA
were Sau3AI and Tsp509I, and the enzyme used to digest
MoMLV DNA was EcoRV.
Bioinformatic analysis of 454 sequencing results
Processing of 454 reads, identification of insertion sites, and
Gaussian kernel convolution (GKC) statistical methods used to
identify common insertion sites (CISs) have been described
previously [6,24,71,72]. In summary, 454 reads were mapped to
the mouse mm9 genome assembly, where the only modification to
the previous alignment procedure was the removal of the
stringency check as to whether an alignment was located
neighbouring a TA dinucleotide site (the insertion locations
preferred by Sleeping Beauty transposons on which the bioinfor-
matics processing method was developed). Reads from the same
sample whose start genomic locations aligned within three
nucleotides of each other were merged together. Reads from the
same sample that were more than three nucleotides apart were
considered independent integration events. CISs were identified
using the multi-scale GKC approach [6,24]
Analysis of sample saturation
In order to determine whether the MLV screen had reached
some level of saturation, the Gaussian Kernel Convolution (GKC)
CIS calls from all 28 samples were analysed using the ACT
software package [73].
ACT considers genomic locations generated by multiple
samples for specific biological phenomenon under study (e.g.
ChIP-seq peaks) to determine the saturation of a screen. The
program considers the various combinations in which samples can
be added so that the increase in base pair coverage is a range of
values based on all the samples. The results can be depicted as a
series of boxplots showing the increase in base pair coverage,
where the boxplot at each position n on the x-axis shows the
coverage values of all combinations of n samples. Boxplots that
approach a horizontal asymptote indicate that the coverage has
reached saturation.
For the GKC CISs generated by all 28 samples, the insertion
sites that contributed to CISs were extracted, resulting in a set of
7,485 sites. The insertion sites were then selected per sample and
pseudo-kernels of 7.5k nucleotides either side of each insertion
were applied to mimic GKC kernels of 15k nucleotides.
Overlapping kernels within each sample were merged into
continuous genomic regions. These 28 modified insertions files
were then analysed using ACT. For each combination of samples
the median values, and 25th and 75th percentiles were plotted
using ggplot2 [74].
As a control, the 28 samples were re-analysed where the same
number of insertion sites per sample were selected at random
across the mouse genome. The pseudo-15k nucleotide kernels
were applied.
While the analysis does not produce a clear-cut asymptote this is
to be expected due to the type of data under consideration. ACT
was designed to analyse such data as ChIP-seq arrays for
predicting transcription factor binding sites. In these scenarios
ChIP-seq replicates should ideally report the same key binding
sites/genomic locations. Hence across multiple samples the same
locations should be reported.
For MLV screens however, while insertions in the same gene
will be found from different samples, the locations of the insertion
sites will not overlap perfectly, even with the addition of the 15k
nucleotide pseudo kernels. Hence each sample will introduce novel
regions, such that the overall coverage will continue to increase
even if the screen has truly reached a ‘saturation’ point. Also not
all samples will contribute to all CISs. Different combinations of
samples will thereby result in varying coverages, causing the
coverage profile not to asymptote perfectly.
Integration site location mapping relative to
transcription start sites (TSS)
The genomic coordinates of the ‘UCSC Genes’ set was
downloaded via the UCSC genome browser for mouse assembly
mm9. Each of the 12,485 MoMLV integration sites was then
mapped relative to the transcription start site (TSS) of its closest
UCSC-defined ‘known’ gene.
Bioinformatic analysis of Kool et al. 2012 insertion sites
The Kool set of 19,923 mouse retroviral insertions sites was
downloaded from the Mutapedia website (http://mutapedia.nki.
nl/) [3]. In the original paper, 596 CISs were identified using the
GKC statistical framework with a fixed kernel width of 30k
nucleotides. The insertion sites were re-analysed using the same
multi-scale kernel approach that was applied to the MoMLV
insertion sites. As a result of the multi-scale kernels and a less
stringent cut-off value, 977 CISs were identified.
Defining the width of a CIS as spanning the minimum and
maximum genomic coordinates of insertion sites that contribute to
a CIS, CISs were compared between the progression set and the
re-analysed Kool set for overlaps. CISs were called overlapping if
at least one nucleotide was overlapping between the two CIS sets.
Integration site orientation bias analysis
MLV CISs from this study. For each MoMLV CIS, the
integration sites that contributed to it were collated, divided into
forward- and reverse-orientation sites, and their frequencies
counted. A one-tailed Fisher’s exact test was then performed
using the frequencies of the CIS-specific integrations versus the
frequencies of remaining integration sites not present in the current
CIS. Multiple test correction was performed using the Benjamini-
Hochberg procedure [75].
MLV vector CISs in CD34+ cells
A set of 32,592 human MLV-based vector integration sites was
kindly provided by Cattoglio and co-workers as previously
published [21]. In the original study genomic regions were
considered as significant if three or more integration sites were
found clustered within regions of 12,587 nucleotides. This
threshold was applied to the 32,592 integrations sites resulting in
the identification of 3,453 clusters. Taking the integration sites
within the clusters, a similar Fisher’s exact test method was used to
assess the orientation bias of the integration sites as for the
MoMLV CISs. Following multiple test correction no clusters
exhibited any orientation bias.
Microarray analysis
RNA was isolated and purified from the thymuses of 10 day old
wild type and CD2-MYC/Runx2 double transgenic mice using an
RNeasy Mini Kit as per the manufacturer’s instructions (Qiagen,
UK) with mechanical lysis using a pellet pestle in a microfuge tube
(Sigma). RNA purity was assessed using a Nanodrop 2000
Spectrophotometer (Thermo Scientific), and integrity verified
using the Agilent 2100 Bioanalyser with RNA 6000 Nano
Reagents kit (Agilent Biotechnologies) as per the manufacturer’s
protocol. Whole genome expression profiling was performed using
Affymetrix mouse GeneChip microarrays (MoGene-1) in triplicate
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as per the manufacturer’s protocol (Affymetrix, UK). Data analysis
was carried out using the Partek Genomic Suite (Partek Inc., St.
Louis, MO, USA). Briefly, after Robust Multichip Average
normalisation [76] with GC content pre-background adjustment,
the differentially expression analysis was performed using
ANOVA. Multiple testing correction was done using the ‘q value’
cut-off [77] with gene changes of p,0.05 considered significant.
Graphical representations of data were prepared using CLC
Genomics Workbench 4.
Supporting Information
Figure S1 (a) Basic features of the lymphoma model. Expression
of either Runx2 orMYC under the control of the CD2 locus control
region leads to a low lifetime incidence of T-cell lymphoma. This
appears to be due to the variegated activation of the transgenes
and counter-selection for expressing cells which either die by
apoptosis (MYC) or grow slowly with impaired differentiation
(Runx2). The combination of both transgenes cancels these failsafe
responses and leads to early onset lymphoma in a 100% of mice
[8,17,18,23]. Tumour onset can be accelerated further by neonatal
infection with Moloney murine leukaemia virus (MoMLV) [26]. (b)
The clonal nature of CD2-Runx2/MYC lymphomas is demon-
strated by rearrangements of the T-cell receptor b-chain. Southern
blot analysis of 20 mg samples of DNA digested with HindIII and
analysed with a Cb probe. The virtual disappearance of the
unrearranged Cb1 is due to the replacement of non-lymphoid cells
by lymphoid cells carrying deletions or rearrangements of Cb1. As
TCR rearrangement can result in productive rearrangement or
deletion of Cb1, dominant clones may be represented by one or two
bands. As can be seen, spontaneous tumours in these mice typically
display a single major clone, although some evidence of minor
clones is present in some cases (-MoMLV). In MoMLV accelerated
tumours, there is typically a more complex pattern indicative of
greater clonal complexity. Due to the limited sensitivity of Southern
blot analyses, clones representing less than 5% of the tumour mass
are not detectable. c Phenotypic analysis of CD4 and CD8
expression in primary thymic lymphoma CD2-Runx2/MYC mice.
Note that normal thymocytes were almost completely replaced by
the characteristic bi-modal tumour cell population (.96–99%). No
phenotypic difference was observed in MoMLV-accelerated
lymphomas.
(TIF)
Figure S2 (a) Evidence that expanding clones in virus-
accelerated Runx2/MYC lymphomas contain a single provirus.
The top 40 RISs (in rank order by number of reads) shows few
insertions at isolated RIS far from known target genes(5/40),
although these predominate (85%) in the total population of
12,485 RISs. If clonal expansion required two or more hits of
proviral insertion, we would expect many more instances of co-
amplification of passenger RIS (grey bars). (b) There is a
correlation between splinkerette 454 sequence reads and Southern
blot detection of rearrangement, with insertions at Pim1 in
expanded tumours clones in tumours 20i and 13i being detected
by both methods at similar relative efficiency (compare to (a)). G:
germ line; R: retrovirus insertion.
(TIF)
Figure S3 Additional MLV insertion patterns at other biased
and non-biased CISs. Each vertical bar represents an individual
RIS, red indicates reverse orientation compared to the+strand,
green the same orientation. The positions of exons and introns
were extracted from the UCSC genome browser (NCBI37/mm9).
(TIF)
Figure S4 KEGG Cytoscape plot. Genes with RIS counts of 3
or more are visualized in the context of their KEGG pathway
interactions using Cytoscape. The KEGG network is based on
metanodes. A metanode is a collection of genes that share similar
function. Some metanodes only contain a single gene. Links in the
KEGG network denote a functional interaction between any of
the genes in the two metanodes connected by the link. For
visualization purposes the metanodes themselves are not displayed.
Consequently, in the resulting graph a link between two genes is
present if there is a link between the metanodes in which these
genes reside. Blue links are KEGG pathway links, red links
connect genes that are in the same metanode in KEGG. Genes
that are in the same metanode share functionality (according to
KEGG). Note that metanodes are not necessarily consistent across
different pathways, which is why some genes that are in the same
metanode have a different set of interaction partners. Node colour
and size represents the number of RIS attributed to that gene: blue
and small circle: 3 RIS, red and large circle: up to a maximum of
127 RIS.
(TIF)
Figure S5 KEGG pathway enrichment analysis. The effects on
pathway analysis of limiting gene sets by number of hits or removal
of most prominent CISs. This analysis was conducted to test the
extent to which oncogenic selection is present throughout the
detected RISs. Box plots represent log10 p-values for all pathways
in the KEGG database. The legend lists the pathways with a
significant p-value (at the 1610E-5 level) for at least one of the
discovery set definitions, with the minimum p-value between
parentheses. The leftmost box depicts the log10 p-values of the
pathway enrichment when the discovery set is defined as all genes
associated with five or more RISs. For the second box from the left
the discovery set is defined as all genes with at least one associated
RIS. This is also the case for box 3 through 6, but in those
discovery sets the top 20, 50, 100 and 500 most frequently targeted
genes are removed from the discovery set, respectively. The
horizontal red line indicates the 1025 significance level. Surpris-
ingly, enrichment is more significant when the entire ‘integrome’ is
analysed than when restricted to genes that are frequently targeted
(by 5+ RIS). Moreover, removal of 20 to 100 ‘top hit’ genes which
includes genes common to many of the annotated pathways (e.g.
Ccnd, PI3K, Pim gene families) has relatively modest effects on
significance scores, while enrichment for pathways in cancer and
others survives even the removal of the top 500 genes. These
results strongly indicate that either a) the majority of RISs,
including those that are not common across multiple tumours,
have been subjected to oncogenic selection or b) viral targeting of
these pathways is an underlying phenomenon based on integration
preference.
(TIF)
Figure S6 (a) Quantitative real-time PCR validation of key gene
changes observed in the microarray. Quantification is relative to
house-keeping gene TBP for genes in the CC chemokine family,
with fold changes and significance as determined by two-tailed
unpaired student’s T-test shown in (b) Error bars represent S.E.M.
Genes with fold differences reaching a q,0.05 significance
threshold in the microarray are noted with an asterisk (*). N/
A=gene not present on the microarray.
(TIF)
Figure S7 Lack of expression of CC chemokine genes in
lymphoma cells from Runx2/MYC and other genetic back-
grounds. Quantitative real-time PCR analysis of CC chemokine
receptors and ligands for a number of T-cell lymphoma lines from
Runx2/MYC (GIM) or p53null/MYC (p/m) backgrounds,
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expressed relative to adult normal thymus, with HPRT as control.
(a) Ccr7 and ligands (b) Ccr9 and ligand. (c) Significance of down-
regulation of CC ligands compared to receptors in T-cell lines,
determined by two-tailed unpaired student’s T test. Errors
represent standard error (SEM).
(TIF)
Table S1 Master list of all CISs showing CIS chromosomal
location and peak height, plus associated genes. Also shown is the
number of insertions in each CIS.
(XLSX)
Table S2 .bed file of all GIM1 alignments, showing chromo-
somal locations, tumour identity, read counts and strand polarity.
(XLSX)
Table S3 The top 25 progression CISs, ordered by the number
of insertions. Gene names and annotations are shown, as are the
total number of insertions, the number of tumours with insertions
and the average number of reads per RIS for each gene. Genes in
bold were previously identified as targets by shotgun cloning.
(TIF)
Table S4 Overlapping CISs found in both this screen and the
Kool et al. screen, showing CIS chromosomal locations and gene
identities.
(XLSX)
Table S5 CISs with significant orientation bias, showing gene
identities, the total number of insertions, the percentage bias and p
values with Benjamini multiple testing correction. Also shown is
the rank order of the CIS in the Kool et al. screen.
(TIF)
Table S6 Most frequent intragenic insertions without orienta-
tion bias. Unbiased/intragenic CIS locations and target genes
identified from the RIM screen, ordered by number of insertions
are shown. Also shown are the number of hits in the Retrovirus
and Transposon Tagged Cancer Gene Database (RTCGD, Akagi
et al., Nucleic Acids Res., 2004, 32: D523–527), and the rank-order
position of the gene in terms of peak height from a total of 823 CIS
in the Kool et al. data set. N/A denotes the absence of the gene in
the Kool et al. CIS list.
(TIF)
Table S7 CISs displaying loss of selection in Runx2/MYC
lymphoma progression compared to end-stage lymphomas. Some
of the most strongly selected target genes in the Kool et al. meta-
analysis of 956 lymphomas are notably under-represented in the
Progression CISs. This is illustrated in the table where the most
discordant examples are compared by CIS peak height (a measure
of number hits and degree of clustering) and rank order. A nil
entry (-) means that no CIS was recorded in the progression
dataset. For comparison, several prominent targets that are shared
are listed below. Grey shading denotes reduced selection com-
pared to the meta-analysis.
(TIF)
Table S8 Top targets unique to Huser et al. dataset showing
gene name and function, peak height and evidence of that gene’s
role in human cancer.
(PPTX)
Table S9 List of CISs from GIM set 2, showing chromosomal
location and associated genes.
(XLSX)
Table S10 .bed file of all GIM2 alignments, showing chromo-
somal locations, tumour identity, read counts and strand polarity.
(XLSX)
Table S11 Number of insertions in end-stage lymphomas of
three genotypes (wild-type, Runx2, MYC) for the top 25
progression CISs (from analysis 1). The numbers of expanded
clones (RIS with .100 reads) are listed in brackets.
(TIF)
Table S12 The number of insertions in end-stage tumours of
three genotypes (wild-type, Runx2 and MYC) is shown for the
most frequent targets for intragenic insertions in the progression
network. Numbers in brackets denote expanded RIS (.100 reads).
(TIF)
Table S13 CIS biased by genotype, sorted by genotype in end-
stage lymphomas. Number of RIS are shown alongside number of
reads/RIS separated by |. Shading denotes apparent positive
selection (reads/RIS.10). In some cases there are clear qualitative
differences that are not amenable to statistical comparison due to
small numbers of RISs (e.g. Mycn). Significant differences for
insertions * at Runx2 between Runx2 and MYC genotypes
(P = 0.021) and ** at Ikzf1 between WT and MYC (P=0.034) and
between Runx2 and MYC (P=0.04) (Mann-Whitney U test).
(TIF)
Table S14 Comparison of Maser et al. genomic regions that are
amplified or deleted in TKO mouse and human T-ALL with
Huser et al. CIS regions. Shown are the chromosome locations of
the syntenic regions (common MCRs=minimal critical regions)
from Maser et al., and the start, end and peak locations as well as
peak height of CIS coinciding with these regions. Also shown are
gene annotations for CIS and whether the CIS is intragenic or not.
The CIS at Gpr132 is both intragenic and upstream of the gene
and is labelled +/2. 43/771 CISs map to the syntenic regions
which encompass 79.7 Mb of genomic sequences. To assess the
probability of this overlap, the mouse genome was considered as a
series of 30 kb ‘bins’, the average size of the defined CISs. On this
basis, the syntenic regions occupy 2613/89796 bins. The
probability of the observed overlap based on the contingency
table below is P=,0.0001 (http://vassarstats.net/tab2x2.html).
(TIF)
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